Glen Fandetti, MD
Interventional Cardiology · Charlotte, NCNPI 1265656094
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Heartflow, Inc. accounts for 90.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $19,484 and has fallen 56.9% since, to $8,389 in 2025.
Across 144 payments — averaging $321.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$42K
- Abbott$1K
- Boston Scientific$977
- Inari Medical, Inc.$413
- Stryker$304
- Abiomed$278
- plus $1K from 18 others
Across 1 payment — averaging $108.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$108
What the payments were for
- Consulting fees$19,91443%
- Speaking & faculty fees$18,89041%
- Travel & lodging$1,7994%
- Food & beverage$5,63812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 51 | $41,953 |
| Abbott | 15 | $1,068 |
| Boston Scientific | 16 | $977 |
| Inari Medical, Inc. | 4 | $413 |
| Stryker | 2 | $304 |
| Abiomed | 6 | $278 |
| Medtronic | 7 | $246 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $133 |
| Teleflex LLC | 1 | $130 |
| Shockwave Medical, Inc | 5 | $123 |
| Novartis | 5 | $107 |
| Philips North America LLC | 2 | $78 |
| Scpharmaceuticals Inc. | 2 | $69 |
| Johnson & Johnson | 3 | $67 |
| Cook Medical LLC | 1 | $42 |
| Convatec Inc. | 2 | $41 |
| Cardiva Medical, Inc. | 2 | $39 |
| Thrombolex, Inc. | 2 | $35 |
| Terumo Medical Corporation | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Pfizer | 2 | $28 |
| Boehringer Ingelheim | 1 | $19 |
| Imperative Care, Inc | 1 | $17 |
| Livanova USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$41,543
- CARDIOMEMS$507
- FlowTriever$482
- AVVIGO Guidance System$324
- CardioMEMS HF System$242
- ClotTriever$178
- FLOWTRIEVER CATHETER, S$152
- CT THROMBECTOMY SYSTEM KIT$152
- GENERAL ANGIOGRAPHY$150
- Impella$135
- ONYX FRONTIER$132
- GUIDELINER$130
- TRICLIP$124
How this compares
$46,240 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $107,401 |
| Repatha SureclickEvolocumab | 45 | $36,022 |
| XareltoRivaroxaban | 18 | $23,471 |
| LipitorAtorvastatin Calcium | 11 | $3,144 |
| ClopidogrelClopidogrel Bisulfate | 271 | $2,491 |
| Atorvastatin Calcium | 272 | $2,298 |
| Nitroglycerin | 140 | $1,326 |
| Metoprolol Succinate | 88 | $1,214 |
| Ezetimibe | 40 | $936 |
| Rosuvastatin Calcium | 69 | $742 |
| Carvedilol | 92 | $729 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $683 |
| Metoprolol Tartrate | 130 | $654 |
| Losartan Potassium | 59 | $373 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 16 | $274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lipitor | $28 | $110,545101 claims |
| Johnson & JohnsonXarelto | $67 | $23,47118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Charlotte
- Oluseun AlliCharlotte$485K
- John PasquiniCharlotte$32K
- Aamer QureshiCharlotte$27K
- Daniel PuCharlotte$23K
- Nyal BorgesCharlotte$18K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.